OM:PHLOG B

Stock Analysis Report

Pharmacolog i Uppsala

Executive Summary

Pharmacolog i Uppsala AB (publ), a medical device company, provides solutions for the safe administration of medical drugs in Sweden.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Pharmacolog i Uppsala's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.7%

PHLOG B

-1.0%

SE Medical Equipment

2.9%

SE Market


1 Year Return

177.5%

PHLOG B

26.1%

SE Medical Equipment

9.0%

SE Market

Return vs Industry: PHLOG B exceeded the Swedish Medical Equipment industry which returned 26.1% over the past year.

Return vs Market: PHLOG B exceeded the Swedish Market which returned 9% over the past year.


Share holder returns

PHLOG BIndustryMarket
7 Day3.7%-1.0%2.9%
30 Day20.7%-0.05%-0.4%
90 Day9.4%-7.0%0.3%
1 Year199.9%177.5%27.4%26.1%13.7%9.0%
3 Year-44.8%-66.6%44.1%26.9%30.5%11.1%
5 Yearn/a68.2%40.4%66.0%30.7%

Price Volatility Vs. Market

How volatile is Pharmacolog i Uppsala's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pharmacolog i Uppsala undervalued based on future cash flows and its price relative to the stock market?

4.25x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate PHLOG B's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate PHLOG B's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: PHLOG B is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: PHLOG B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate PHLOG B's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: PHLOG B is good value based on its PB Ratio (4.2x) compared to the SE Medical Equipment industry average (4.4x).


Next Steps

Future Growth

How is Pharmacolog i Uppsala expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

26.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacolog i Uppsala has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pharmacolog i Uppsala performed over the past 5 years?

-25.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PHLOG B is unprofitable, and losses have increased over the past 5 years at a rate of -25.3% per year.

Accelerating Growth: Unable to compare PHLOG B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PHLOG B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).


Return on Equity

High ROE: PHLOG B has a negative Return on Equity (-52.12%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PHLOG B is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PHLOG B is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Pharmacolog i Uppsala's financial position?


Financial Position Analysis

Short Term Liabilities: PHLOG B's short term assets (SEK28.2M) exceeds its short term liabilities (SEK3.0M)

Long Term Liabilities: PHLOG B's short term assets (28.2M) exceeds its long term liabilities (1.4M)


Debt to Equity History and Analysis

Debt Level: PHLOG B's debt to equity ratio (6%) is considered satisfactory

Reducing Debt: PHLOG B's debt to equity ratio has reduced from 8.9% to 6% over the past 5 years.


Balance Sheet

Inventory Level: PHLOG B has a low level of unsold assets or inventory.

Debt Coverage by Assets: PHLOG B's debt is covered by short term assets (assets are 18.129170x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PHLOG B has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PHLOG B has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -4% each year


Next Steps

Dividend

What is Pharmacolog i Uppsala's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.8%markettop25%4.8%industryaverage1.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate PHLOG B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PHLOG B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PHLOG B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PHLOG B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PHLOG B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

What is the CEO of Pharmacolog i Uppsala's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average board tenure


CEO

Mats Högberg (55yo)

0yrs

Tenure

0

Mr. Mats Högberg serves as the Chief Executive Officer of Pharmacolog i Uppsala AB (publ) and its Director since 2017. Mr. Högberg served as the Vice President of Sales & Marketing at Pharmacolog i Uppsala ...


Board Age and Tenure

2.8yrs

Average Tenure

Experienced Board: PHLOG B's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Buykr165,99604 Jul 19
Mats Högberg
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15,257
Max Pricekr10.88

Ownership Breakdown


Management Team

  • Hans Dahlin

    Founder

    • Tenure: 9.8yrs
  • Kent Öbrink (54yo)

    Sales & Marketing Manager

    • Tenure: 2.1yrs
  • Mats Högberg (55yo)

    CEO & Director

    • Tenure: 0yrs

Board Members

  • Erik Hedlund (71yo)

    Chairman of the Board

    • Tenure: 2.7yrs
  • Hans Dahlin

    Founder

    • Tenure: 9.8yrs
  • Olle Johansson

    Director

    • Tenure: 0yrs
  • Mats Högberg (55yo)

    CEO & Director

    • Tenure: 0yrs

Company Information

Pharmacolog i Uppsala AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharmacolog i Uppsala AB (publ)
  • Ticker: PHLOG B
  • Exchange: OM
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr110.153m
  • Shares outstanding: 9.92m
  • Website: https://www.pharmacolog.com

Location

  • Pharmacolog i Uppsala AB (publ)
  • Ekeby bruk
  • Uppsala
  • Uppsala County
  • 752 75
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHLOG BOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2015
PUPP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2015

Biography

Pharmacolog i Uppsala AB (publ), a medical device company, provides solutions for the safe administration of medical drugs in Sweden. Its lead product is DrugLog, a system used to prevent drug administrati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 23:49
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)